INNOVATE Corp

VATE

Market cap $70.3M

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, announced that the peer-reviewed transdermal GFR measurement article published in the Journal of the American Society of Nephrology (JASN) has been recognized as one of five 2025 Editor's Choice articles.1

NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated steel construction services, and an operating subsidiary of INNOVATE, will pay a cash dividend of approximately $5 million, or $1.30 per share, on February 24, 2026 to DBMG's stockholders of record at the close of business on February 9, 2026. As the largest stockholder of DBMG, INNOVATE expects to receive approximately $4.6 million of the total $5 million dividend payout. INNOVATE's individual stockholders are not eligible to receive the cash dividend.

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, has received approval from the U.S. Food and Drug Administration (FDA) for the next generation MediBeacon® TGFRTM System including the latest TGFRTM Reusable Sensor.

INNOVATE Corp. ( VATE ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Neel Sikka Paul Voigt - Interim Chief Executive Officer Michael Sena - CFO, Treasurer & Corporate Secretary Presentation Operator Good afternoon, and welcome to the INNOVATE Corp Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

- Infrastructure: DBM Global delivers robust revenue growth, reinforcing market leadership - - Life Sciences: MediBeacon received regulatory approval to sell the Transdermal GFR System in China - - Spectrum: New network launches underway; F ourth quarter advertising sales showing early signs of recovery -

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the third quarter 2025 on Wednesday, November 12, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET.

NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, and an equity method investment of INNOVATE, has received approval from the National Medical Products Administration (NMPA) for Lumitrace® (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR agent. Lumitrace will be sold as an integral component of the Transdermal GFR System in China.

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated steel construction services, and an operating subsidiary of INNOVATE, will pay a cash dividend of approximately $8.8 million, or $2.28 per share, on November 10, 2025 to DBMG's stockholders of record at the close of business on October 27, 2025. As the largest stockholder of DBMG, INNOVATE expects to receive approximately $8 million of the total $8.8 million dividend payout. INNOVATE's individual stockholders are not eligible to receive the cash dividend.

NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced that R2 Technologies, Inc. (“R2”), the innovators behind the breakthrough Glacial® Skin technology, and an operating subsidiary of INNOVATE, achieved a second-quarter 2025 revenue increase of 88% over the same quarter in 2024. This strong performance underscores R2's accelerating momentum in the global aesthetics market.

INNOVATE Corp. (NYSE:VATE ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Michael J. Sena - CFO, Treasurer & Corporate Secretary Neel Sikka - Corporate Participant Paul Kenneth Voigt - Interim Chief Executive Officer Operator Good afternoon, and welcome to INNOVATE Corp.'s Second Quarter 2025 Earnings Conference Call.